

**09/22/2022**

## **Clarification Regarding Outpatient Pharmacy CHIP Copayments for COVID-19 Vaccines, Treatment, and Testing**

Clarification Regarding Outpatient Pharmacy CHIP Copayments for COVID-19 Vaccines, Treatment, and Testing

### **Background:**

The American Rescue Plan Act (ARPA) requires CHIP MCOs to provide COVID-19 vaccines, COVID-19 testing, and treatment of COVID-19 without imposing cost-sharing.

### **Key Details:**

To comply with the American Rescue Plan Act's (ARPA) amendment to Sections 2103(c)(11) (B) and 2103(e)(2) of the Social Security Act, CHIP MCOs must provide COVID-19 vaccines, COVID-19 test kits, and COVID-19 treatments without imposing copayments. MCOs must cease collecting copayments for outpatient pharmacy claims from CHIP members by December 21, 2022. MCOs must follow the directions below for reimbursement of waived CHIP copayments. CHIP MCOs must notify members and providers of this policy for all CHIP members.

### **• Pharmacy: Applicable Drugs and Products**

This policy applies to copayments for all CHIP formulary COVID-19 vaccines, test kits, and drugs indicated for the treatment of COVID-19. The drugs, Paxlovid and Molnupriavir, are indicated for the treatment of COVID-19. The national drug codes (NDCs) in the table below are on the formulary for Medicaid and CHIP as a reimbursable pharmacy benefit:

<b>Drug name</b>	<b>Dosage</b>	<b>Package size</b>	<b>NDC</b>	<b>Formulary Effective Coverage date</b>
Paxlovid EUA	2X150mg-100mg	6 tablets	00069-1085-06	12/27/2021
Paxlovid EUA	2X150mg-100mg	30 tablets	00069-1085-30	12/27/2021
Paxlovid EUA	2X150mg-100mg	6 tablets	00069-0345-06	04/30/2022
Paxlovid EUA	2X150mg-100mg	30 tablets	00069-0345-30	04/30/2022
Paxlovid EUA	150-100mg	4 tablets	00069-1101-04	04/30/2022
Paxlovid EUA	150-100mg	20 tablets	00069-1101-20	04/30/2022

Molnupiravir EUA

200 mg

40 capsules

00006-5055-06

12/27/2021

Refer to the [Formulary Product Search](#) to identify applicable COVID-19 [vaccines](#) and [test kits](#).

